First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis

Genitourinary Cancer

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

JAMA Oncol

Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L

doi: 10.1001/jamaoncol.2025.1891

Gastrointestinal Cancer

Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-Analysis

Oncologist

Reimann P, Schneider EM, Djanani A, Mink S, Winder T, Benda M

doi: 10.1093/oncolo/oyaf224

Lymphoma

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy

Blood Cancer J

Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Danilov A, Argao C, Ruan J, Nizamuddin IA, Kahl BS, Grover NS, Khan NB, Pongas GN, Lossos IS, Ouchveridze E, Tun AM, Baidoun F, Alhaj Moustafa M, Harris ZI, Munoz JL, Young PR, Portell CA, Reagan PM, Ryan CE, Merryman RW, Velayati A, Greenwell IB, Gerber DG, Jain P, Wang ML, Ayyappan SR, Mou E, Banaszak LG, Pophali PA, Stack AC, Messmer MR, Narkhede MS, Mehta A, Moyo TK, Ghosh N, Bhansali RS, Barta SK, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P

doi: 10.1038/s41408-026-01507-w

Lung, Respiratory and Thoracic Cancer

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis

Lung Cancer

Alexander M, Itchins M, Felthun J, Nagrial A, Brown LJ, O'Byrne K, Mersiades AJ, Hughes BGM, Warburton L, Kong BY, Moore M, Blinman P, Bowyer S, Clay T, Spelman T, Pavlakis N, Solomon BJ, Kao S

doi: 10.1016/j.lungcan.2025.108854

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Wang Y, Zhang L, Zhan J, Wen L, Zhao X, Sun H, Chen X, Zhang Y, Chen G, Zhao Y, Huang Y, Fang W, Zhang L, Sun D, Yang Y

doi: 10.1016/j.lungcan.2026.108914

Lung, Respiratory and Thoracic Cancer

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Lung Cancer

Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S

doi: 10.1016/j.lungcan.2026.109305

Lung, Respiratory and Thoracic Cancer

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC

Clin Cancer Res

Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X

doi: 10.1158/1078-0432.CCR-25-1735

Gynecologic Cancer

Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis

Cancer Treat Rev

Andrade MO, Al-Alam OCM, Kim HJS, Batista JPT, Dornellas DMS, Coelho RL, Borges VEL, Gouveia MC, Scaranti M, Bonadio RC, Gaillard S, Costa SCS

doi: 10.1016/j.ctrv.2025.102959

Further Publications

Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis

JAMA Oncol

Celsa C, Di Maria G, Lombardi P, D'Alessio A, Fulgenzi CAM, Brunetti L, Manfredi GF, Stefanini B, Sparacino A, Rigamonti C, Pirisi M, Latchford C, Vaccaro M, Enea M, Cammà C, Cabibbo G, Pinato DJ

doi: 10.1001/jamaoncol.2025.2470

Related content

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-Analysis

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC

Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis

Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis